Johnson & Johnson $JNJ Stock Sold by State of Alaska Department of Revenue

Key Points

• Alaska’s Department of Revenue reduced its Johnson & Johnson stake by 2.5%, selling 7,583 shares and retaining 291,166 shares valued at approximately $77.1 million. Institutional investors collectively own 69.55% of J&J.
• Johnson & Johnson reported third-quarter adjusted earnings of $2.59 per share and $25.40 billion in revenue, beating estimates, while raising its 2026 adjusted EPS guidance to approximately $11.05–$11.15.
• Despite strong results and a “Moderate Buy” consensus rating, investors face concerns over weaker-than-expected MedTech sales, potential restructuring or spinoff costs, analyst price-target reductions, and the stock’s premium valuation.

State of Alaska Department of Revenue lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 291,166 shares of the company's stock after selling 7,583 shares during the period. Johnson & Johnson accounts for 0.7% of State of Alaska Department of Revenue's portfolio, making the stock its 21st largest position. State of Alaska Department of Revenue's holdings in Johnson & Johnson were worth $77,082,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of the stock. Outlook Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $28,000. Matrix Trust Co raised its position in shares of Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after acquiring an additional 54 shares during the last quarter. Hyposwiss Advisors SA bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $42,000. Montgomery Financial Services LLC acquired a new position in shares of Johnson & Johnson during the second quarter valued at $43,000. Finally, Polaris Financial Partners acquired a new position in shares of Johnson & Johnson during the third quarter valued at $56,000. Institutional investors own 69.55% of the company's stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported third-quarter adjusted earnings of $2.59 per share and revenue of $25.40 billion, exceeding consensus estimates. Revenue increased 5.9% year over year, led by 7.9% growth in Innovative Medicine. J&J Q3 2026 Earnings Call Transcript
• Positive Sentiment: Management raised its 2026 sales and earnings outlook, with guidance of approximately $11.05–$11.15 in adjusted EPS. Executives also highlighted pipeline products and MedTech innovation as potential sources of future growth. JNJ Q3 Earnings Call Highlights
• Positive Sentiment: Morgan Stanley maintained an “overweight” rating, while RBC retained an “outperform” rating, indicating that analysts still see potential upside despite trimming their price targets. Technical analysts also identified support near $246. Morgan Stanley JNJ Price Target
• Neutral Sentiment: Johnson & Johnson plans an enterprise review on December 8 and is targeting a potential mid-2027 spinoff of its DePuy Synthes orthopedics business. These initiatives could clarify the company’s growth strategy but may also create execution and earnings-dilution concerns. J&J MedTech Orthopedics Spinoff
• Negative Sentiment: MedTech sales missed Wall Street expectations, with weakness attributed partly to China pricing pressure and European budget cuts. Investors viewed the device business as a key reason the stock fell sharply following earnings. Johnson & Johnson Stock Falls as MedTech Misses
• Negative Sentiment: Analysts lowered several price targets after the results, citing mixed pharmaceutical trends, acquisition costs, talc-related charges and potential 2027 dilution. The concerns are more significant because JNJ trades at a premium earnings multiple versus the broader market. Analysts Cut JNJ Forecasts

Analysts Set New Price Targets

A number of brokerages recently commented on JNJ. Wall Street Zen lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Tuesday, September 29th. HSBC upped their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a research report on Thursday, September 10th. Weiss Ratings raised shares of Johnson & Johnson from a "buy (b)" rating to a "buy (b+)" rating in a research note on Thursday, October 8th. Finally, Freedom Capital upgraded shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $274.35.

Insider Buying and Selling

In other news, EVP Jennifer Taubert sold 15,000 shares of the company's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 87,569 shares of company stock valued at $23,064,544. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Down 0.1%

NYSE:JNJ opened at $253.68 on Friday. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12-month low of $184.66 and a 12-month high of $281.07. The stock's fifty day simple moving average is $265.73 and its 200-day simple moving average is $249.57. The firm has a market capitalization of $611.35 billion, a P/E ratio of 38.44, a P/E/G ratio of 2.59 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter in the prior year, the company posted $2.80 earnings per share. The firm's revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts expect that Johnson & Johnson will post 11.10 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's payout ratio is presently 81.21%.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.